UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 10, 2000
---------------
SANGUI BIOTECH INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of incorporation)
0-21271 84-1330732
---------------- ------------------------
(Commission File Number) (IRS Employer Identification No.)
1508 BROOKHOLLOW DRIVE, SUITE 354
SANTA ANA, CALIFORNIA 92705
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(714) 429-7807
-------------------------
Registrant's telephone number, including area code:
Not applicable
---------------------------------
(Former name, address and telephone number)
1
<PAGE>
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
Effective July 10, 2000, the Board of Directors of the Company approved the
engagement of Corbin & Wertz Certified Public Accountants as its independent
auditors for the fiscal year ending June 30, 2000 to replace Ernst & Young
Deutsche Allgemeine Treuhand AG Wirtschaftsprufungsgesellschaft (Ernst & Young)
who declined to stand for reelection.
The report of Ernst & Young on the Company's financial statements for the six
months ended June 30, 1999 did not contain an adverse opinion or a disclaimer of
opinion and were not qualified or modified as to uncertainty, audit scope, or
accounting principles.
In connection with the audit of the Company's financial statements for the six
months ending June 30, 1999, and in the subsequent interim period preceding the
date Ernst & Young declined to stand for reelection, there were no disagreements
with Ernst & Young on any matters of accounting principles or practices,
financial statement disclosure, or auditing scope and procedures which, if not
resolved to the satisfaction of Ernst & Young would have caused Ernst & Young to
make reference to the matter in their report. The Company has requested Ernst &
Young to furnish it a letter addressed to the Commission stating whether it
agrees with the above statements. A copy of that letter, dated August 3, 2000
is filed as Exhibit 1 to this Form 8-K/A.
EXHIBITS
16.1 LETTER DATED AUGUST 3, 2000, FROM ERNST & YOUNG REGARDING ITS
CONCURRENCE WITH THE STATEMENTS MADE BY THE REGISTRANT IN THIS CURRENT
REPORT.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report on Form 8-K to be signed on its behalf
by the undersigned hereunto duly authorized.
SANGUI BIOTECH INTERNATIONAL, INC.
/s/ Wolfgang Barnikol
----------------------------------
President and Chief Executive
Officer
Date: August 3, 2000
